US › Healthcare

Lakefront Biotherapeutics NV (LKFT)

US · Healthcare · Biotechnology

$28.91+5.01%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$12.1M

Revenue YoY

-81.4%

Net profit

$2.1M

EPS

$0.03

EPS estimate

$-11.50

Net margin

17.4%

EPS came in at 0.03 against a street estimate of -11.50 — a beat of 100.3%.

Key statistics

Market cap

$1.76B

P/E

2.6

Forward P/E

344.8

P/B

0.46

Book value

$2.89

EPS (TTM)

$10.49

52-week high

$37.78

52-week low

$25.68

50-day MA

$28.50

200-day MA

$30.32

Beta

0.12

Analyst view

with an average price target of $23.73.

Shareholding

Insiders

25.45%

Institutions

23.64%

Largest institutional holders

Fund	Stake
TANG CAPITAL MANAGEMENT LLC	5.78%
Madison Avenue Partners, LP	3.76%
Prosight Management, LP	3.12%
EcoR1 Capital, LLC	2.55%
Ameriprise Financial Inc	2.18%
Point72 Asset Management, L.P.	0.51%
Renaissance Technologies Corp	0.48%
BlackRock Inc	0.48%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lakefront Biotherapeutics NV — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.